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The melanocortin-4 receptor (MC4R) is a potential drug target for treatment of obesity,
anxiety, depression, and sexual dysfunction. Crystal structures for MC4R are not
yet available, which has hindered successful structure-based drug design. Using
microsecond-scale molecular-dynamics simulations, we have investigated selective
binding of the non-peptide antagonist MCL0129 to a homology model of human MC4R
(hMC4R). This approach revealed that, at the end of a multi-step binding process,
MCL0129 spontaneously adopts a binding mode in which it blocks the agonistic-binding
site. This binding mode was confirmed in subsequent metadynamics simulations, which
gave an affinity for human hMC4R that matches the experimentally determined value.
Extending our simulations of MCL0129 binding to hMC1R and hMC3R, we find that
receptor subtype selectivity for hMC4R depends on few amino acids located in various
structural elements of the receptor. These insights may support rational drug design
targeting the melanocortin systems.
Keywords: MC4R, melanocortin-4 receptor, melanocortin-receptors, ligand binding, ligand selectivity, molecular
dynamics
INTRODUCTION
The agonistic proopiomelanocortin-derived neuropeptides α-, β-, and γ-melanocyte-stimulating
hormone (α-, β-, γ-MSH), the adrenocorticotropic hormone (ACTH) and the inverse agonistic
agouti-related peptide (AgRP) are ligands for five closely related melanocortin receptors (MC1-5R),
a subgroup of class A G-protein coupled receptors (GPCRs) (Gantz et al., 1993; Cone, 2005, 2006;
Dores et al., 2014). The melanocortin system is involved in a plethora of physiological functions,
including pigmentation, steroidogenesis, energy homeostasis, and sexual function (Cone, 2006;
Rodrigues et al., 2015).
MC1R is expressed by the dermal melanocyte and regulates the synthesis of eumelanin (black–
brown pigment) versus phaeomelanin (yellow–red pigment) (Herraiz et al., 2017). The ligand
ACTH acts on MC2R (Liang et al., 2013) and is involved in controlling glucocorticoid levels
(Fridmanis et al., 2017). The exact physiological role of the MC3R is not clear. Potential roles
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include control of energy homeostasis in addition to MC4R or
immune response and circadian rhythms (Girardet et al., 2014;
Mountjoy, 2015). Mice with targeted deletion of MC5R exhibit
a defect in water and thermoregulation (Chen et al., 1997),
and recent studies have suggested MC5R/α-MSH involvement in
modulation of muscle glucose uptake and thermogenesis (Enriori
et al., 2016).
The MC4R is of specific interest in the central melanocortin
pathways, because it is known to regulate food intake, glucose
homeostasis, and energy expenditure (Yang and Tao, 2017). The
huge number of pathogenic heterozygous inactivating MC4R
mutations are the most frequent genetic cause of obesity in
humans (Farooqi et al., 2003). Consequently, MC4R agonists
have been developed as potential therapeutics for obesity (Kievit
et al., 2013; Chen et al., 2015; Kuhnen et al., 2016) and
have been proven effective in treatment of male and female
sexual dysfunctions, whereas MC4R antagonists are potential
anxiolytics that may function as antidepressants or for treating
cancer-induced anorexia (Chaki et al., 2003; Ercil et al., 2005;
Pontillo et al., 2005; Chaki and Okubo, 2007; Lansdell et al., 2010).
Although several clinical trials with MC4R ligands have been
initiated (reviewed in Ericson et al., 2017b), none of these
ligands has yet been therapeutically approved, mainly because of
adverse side effects related to low subtype or signaling selectivity
(Yang and Harmon, 2017; Yang and Tao, 2017). For instance,
the non-selective agonist bremelanotide has been shown to
induce elevated blood pressure in clinical trial for male and
female sexual dysfunction, while the MC4R selective peptide
agonist setmelanotide (10-fold over MC3R) have shown no
adverse effects on either blood pressure or heart rate in an anti-
obesity study (Ju et al., 2018). However, setmelanotide treatment
has impact on skin or hair coloring (Kuhnen et al., 2016).
Additionally, MC4R agonist melanotan-II, a super-potent cyclic
melanotropic peptide, increased blood pressure (Dorr et al.,
1996). Animal models have revealed that MC4R and not MC3R,
to be the receptor subtype responsible for stress-induced anorexia
(Chaki and Okubo, 2007) and more recently an animal study
provided a preclinical proof of concept of the HS014 selective
antagonist in treating post-traumatic stress disorder (Sabban and
Serova, 2018).
Generally, MC4R-targeting molecules can be linear or
cyclic peptides, or small molecules (Goncalves et al., 2018).
A comprehensive understanding of molecules that act at MC4R
may help to design safe and effective anti-obesity drugs (Ju
et al., 2018). Recent medicinal chemistry efforts have focused on
using cyclized peptides, cyclotides, and constrained tetrapeptides
to improve bioavailability, selectivity, and blood-brain-barrier
uptake (reviewed in Zhou and Cai, 2017), whereas more recent
small-molecule ligands development has focused on screening
GPCR-privileged pharmacophores (reviewed in Ericson et al.,
2017a).
Such drug-development problems have been solved for
other GPCRs with the aid of robust structural information
and structure-based drug design (SBDD) (Sabban and Serova,
2018). Whilst the last decade has witnessed a revolution in the
field of GPCR structural biology (Granier and Kobilka, 2012),
structural information regarding the melanocortin receptors
and ligands has been limited to NMR data of AgRP or
standalone transmembrane helix 2 (TM2) of the receptor (Sabban
and Serova, 2018). Biomolecular [molecular dynamics (MDs)]
simulations have been successful in providing missing structural
information for GPCRs (Dror et al., 2011, 2012, 2013; Grossfield,
2011; Kruse et al., 2012; Vanni and Rothlisberger, 2012; Rose
et al., 2014; Clark, 2017). Moreover, homology models based
on high-quality templates in combination with microsecond-
scale unbiased MD refinement (Clark, 2017) have provided
robust experimentally testable structural and thermodynamic
information on GPCRs (Milanos et al., 2016; Saleh et al., 2016,
2017a,b,c).
Using an established metadynamics protocol, we have been
able to predict GPCR-ligand binding -affinities, -modes and
free-energies accurately (Saleh et al., 2017b). Metadynamics
simulations use a history-dependent bias to encourage the
system to explore other areas of the free-energy landscape
that are not accessible using plain MD simulation, even using
special purpose supercomputers (Laio and Gervasio, 2008).
Here, we have used microsecond-scale molecular-dynamics
and metadynamics enhanced sampling to investigate binding
mechanisms and thermodynamics of the selective non-peptide
antagonist MCL0129 to human hMC4R.
These insights were used to unravel the molecular
determinants of MCR subtype selectivity and the antagonistic
properties of MCL0129.
MATERIALS AND METHODS
Homology Modeling of the Initial hMC4R
Conformation in an Inactive State
Human MC4R (hMC4R) is characterized by several specific
properties with respect to the amino acid constitution and related
structural features. In particular:
(i) an extremely short second extracellular loop 2 (ECL2,
constituted by approximately four amino acids),
(ii) a missing cysteine disulfide bridge between the ECL2 and
TM3 which is highly conserved among GPCRs,
(iii) a regular α-helical conformation of TM5 because of a
methionine instead of a proline (Pro5.50) that is highly
conserved in class A GPCRs (Supplementary Figure S1) and
induces a helical kink and bulge,
(iv) the highly conserved class A GPCR motif 7.49NPxxY in
TM7 is a 7.49DPxxY motif,
(v) a disulfide bridge in the third extracellular loop (ECL3)
(Tarnow et al., 2003).
Because these features are of functional importance, we
searched for a structural template that best represents the
criteria described. Using the GPCR-SSFE 2.0 modeling server
(Worth et al., 2017), we found the inactive-state structure of
the lyso-phospholipid sphingosine 1-phosphate receptor [S1PR1,
PDB entry 3V2Y (Hanson et al., 2012)] with a sequence
similarity in the transmembrane region of 56% and a sequence
identity to hMC4R of 30% (Blossum62 matrix, Supplementary
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Figure S1). Such high sequence similarity between the suggested
template and MC4R is important for the accuracy of the
structural model (Costanzi et al., 2016). The template structure
is characterized by a leucine at position 5.50 in TM5 (Ballesteros
and Weinstein, 1995) and in consequence shows a regular
α-helical conformation, as also expected for hMC4R. Moreover,
the disulfide bridge between ECL2 and TM3 is missing but a
disulfide bridge is located in the position proposed for MC4R
(Sabban and Serova, 2018) (Supplementary Figure S1). The
N-terminus of S1PR1 is 40 amino acids long, in comparison
to 39 amino acids in hMC4R. The template structure starts
with residue Ser17, the final MC4R model contains amino acids
Asn17-Pro321.
Structural modifications to generate a human MC4R
homology model were performed with the software Sybyl X2.0
(Certara, Princeton, NJ, United States). For template preparation,
the T4-lysozyme and the co-crystallized ligand were removed,
loop lengths were adjusted by deletion of template amino acids
(e.g., for ECL2) and gaps of missing residues in the loops of the
template structure were closed manually (e.g., in ICL2 and ICL3).
Moreover, missing residues between the N-terminal helical part
and TM1 (between Ala39-Leu47) were added manually. Amino
acids of the receptor-template were substituted with residues of
human MC4R according to a sequence alignment between S1PR1
and hMC4R (Supplementary Figure S1), followed by conjugate
gradient minimization of side chains until convergence to a
gradient of 0.1 kcal/mol.Å with constraint backbone atoms
of the transmembrane helices. This preliminary model was
refined by MD simulations (300 K, 2 ns) of side chains and
loops, followed by energy minimization of the entire model
until convergence to a gradient of kcal/mol.Å. The quality and
stability of the model (Figure 1) were validated by checking
the geometry with the program PROCHECK (Laskowski et al.,
1993).
General Setup of the MD Simulations
Melanocortin receptor models were inserted into a 1-palmitoyl-
2-oleoylphosphatidylcholine (POPC) membrane bilayer
according to the orientation in the OPM database (Lomize
et al., 2006). Parameters for the simulations were generated
using the CHARMM-GUI web interface (Jo et al., 2008; Wu
et al., 2014; Lee et al., 2016) using the CHARMM36 force field
(Huang and MacKerell, 2013) with CgenFF (Vanommeslaeghe
et al., 2010) for ligands with partial charges generated from
AM1-BCC calculations (Jakalian et al., 2002). Ligand molecules
were added 7 Å above the receptor’s extracellular surface. The
appropriate number of sodium and chloride ions was added
to the systems to simulate a physiological salt concentration of
150 mM. Particle-mesh Ewald (PME) (Darden et al., 1993) was
used to treat electrostatic interactions, using a cut-off distance
of 10 Å. The resulting system was geometry-optimized and
then equilibrated for 10 ns followed by a production run. All
simulations used the TIP3P water model. All simulations were
performed using GROMACS 5.0.4 (Pronk et al., 2013) and the
Plumed plug-in 2.1 (Tribello et al., 2014) for the metadynamics
simulations. The simulation systems compromised a box of
75 Å× 75 Å× 110 Å.
FIGURE 1 | The final conformation of the hMC4R model with docked
MCL0129, sodium binding and an unusual organization for the distal end of
helices 7–8.
Metadynamics simulations were performed following a
recently published protocol (Saleh et al., 2017b). We used
a combination of the well-tempered variant (WT) (Laio and
Parrinello, 2002; Barducci et al., 2008) of metadynamics
and funnel metadynamics (FM) (Limongelli et al., 2013).
A metadynamics history-dependent bias was applied along the
component of the z-distance between the relatively immobile Cα
of Trp6.48 deep in the ligand-binding region and the center of
mass of positively charged nitrogen atoms of MCL0129. This
distance was used as the single collective variable. The funnel
restraint was then applied to the relative position on the xy-plane
(restrained to 8 Å radius when fully unbound and allowing 13 Å
radius if around the vestibule or deeper) to ensure better sampling
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for the relevant region of the free energy, because the ligand can
otherwise move extensively in the extracellular solvent without
affecting the free energy. Gaussian hills with an initial height
of 0.48 kcal mol−1 were applied every 1 ps. The hill width was
chosen to be 1 Å. The Gaussian functions were rescaled in the
WT scheme using a bias factor of 20.
Representative structures were extracted along the simulation
of initial docking for each 2 Å window, and used as starting
coordinates for the multiple walker technique (Raiteri et al.,
2006). This ensured faster convergence of the free-energy surface
and enhanced the parallelization. Free energies were calculated
using the PLUMED plug-in (Tribello et al., 2014), as described in
our protocol (Saleh et al., 2017b).
Homology Modeling of the Inactive State
hMC1R and hMC3R Structures
It is reported that the ligand MCL0129 is selective among the
hMCR subtypes (Sabban and Serova, 2018) and we identified
residues in the suggested hMC4R ligand binding site that are
similar, identical, or specific compared to hMC1R, hMC2R,
hMC3R or hMC5R (Supplementary Figure S1). The diverse
amino acids may help explain ligand selectivity between the
MCR subtypes; to test this hypothesis we also performed
binding dynamics with MCL0129 at hMC1R and hMC3R.
The hMC1R and hMC1R models were built based on the
final hMC4R/MCL129 docking complex that resulted from the
5 µs unbiased simulation. For this purpose, the ligand was
deleted from the hMC4R/MCL0129 complex. Missing residues
[such as in hMC3R position Asp110 (ECL1) or Pro226-Ala227
(ICL3)] were inserted manually. Amino acids of the hMC4R
model were substituted with corresponding residues of human
hMC1R and hMC3R, respectively, according to the sequence
alignment (Supplementary Figure S1), followed by conjugate-
gradient minimization of side chains until converging at a
termination gradient of 0.1 kcal/mol.Å with constraint backbone
atoms of the transmembrane helices. These initial hMC1R and
hMC3R models were refined by MD simulations of side chains
and loops (300 K, 1 ns), followed by energy minimization of the
entire model until convergence to a gradient of 0.05 kcal/mol.Å.
RESULTS
In this study, spontaneous binding of the selective
MC4R non-peptide antagonist MCL0129 (1-[(1S)-1-(4-
fluorophenyl)-2-[4-[4-(2-methoxynaphthalen-1-yl)butyl]
piperazin-1-yl]ethyl]-4-propan-2-ylpiperazine) was observed
during 5 µs unbiased MD simulation (Chaki et al., 2003) (see
section “Materials and Methods”). These simulations were
analyzed to
(i) elucidate the pathway and mechanism of MCL0129 binding
to hMC4R,
(ii) detect binding intermediates and calculate binding affinities
of MCL0129 using metadynamics simulations and to
(iii) explore the basic structural features of hMC4R in a
stabilized antagonist-bound inactive state.
Structural Features of the hMC4R
Homology Model
The initial hMC4R model is based on the crystal structure
of a lipid GPCR, the sphingosine 1-phosphate receptor 1
(S1PR1, PDB entry 3V2Y) (Hanson et al., 2012), which
shares high sequence similarity (55%) and identity (30%)
with hMC4R in the transmembrane region (Supplementary
Figure S1). Strikingly, both receptors lack two prominent
structural features: (a) Pro5.50 in TM5 and (b) a disulfide bridge
between TM3 and ECL2. The absence of Pro5.50 [superscripts
are according to the Ballesteros and Weinstein numbering
scheme (Ballesteros and Weinstein, 1995)] (Supplementary
Figure S1), which causes a kink and a bulge in TM5 of
most class A GPCRs (Worth et al., 2017) [as in known
structures of adrenergic-receptors (Sabban and Serova, 2018)
and discussed in detail by Sansuk et al. (2011)], leads to a
straight helix conformation in S1PR1 (Troupiotis-Tsailaki et al.,
2017).
The straight TM5 conformation is maintained in 5 µs
unbiased MD simulations of the hMC4R model. On the
cytoplasmic side, sodium spontaneously binds to a site defined
by Ser581.46, Asp902.50, Ser2957.46, and Asn2947.45 (Figures 1, 2).
Binding of sodium to the highly conserved Asp2.50 has also
been observed in the NMR structure of the MC4R TM2 (Yun
et al., 2015) and in the crystal structures of the protease-activated
receptors 1 and 2 (Zhang et al., 2012; Cheng et al., 2017), as well
as in the high-resolution structure of the A2A adenosine receptor
(Figure 2) (Liu et al., 2012). Finally, a 5–6 Å outward movement
of the distal end of TM7 relative to the template structure was
observed, accompanied by a displacement of helix 8 (H8). H8
swivels inwards between TM1 and TM7 to be fixed by polar
interactions, including a salt bridge between K3148.55 of H8 and
Asp2987.49 of TM7 (Figure 2).
Of note, the crystallization construct used for structure
determination of the S1PR1 template is characterized by
three stabilizing mutations located directly at the interface
of the TM7-H8 junction, at residues Lys2506.29, Ser2516.30,
and Leu2526.31. To test whether these substitutions cause the
observed differences between the S1PR1-template structure
and the final hMC4R model, 2 µs MD simulations were
performed on the S1P1R crystal structure with the original
wild-type amino acids at these three positions. We find that
the S1PR1 wild-type model indeed features high structural
flexibility within this region, with similar RMSD to that
observed in the hMC4R model (>5 Å RMSD, Supplementary
Figure S2).
Multi-Step Binding of the Antagonist
MCL0129 to the hMC4R Model
In the 5 µs unbiased MD simulations described above, one
MCL0129 molecule was placed in the extracellular solvent phase
approximately 7 Å from the hMC4R surface. A funnel-like
restraint centered on the receptor [as described in reference
(Saleh et al., 2017b)] was set to focus sampling of the ligand
close to the binding pocket. It is worth noting that this work
reports the first use of a funnel-like restraint, which has so far
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FIGURE 2 | Structural–functional specificities observed in the hMC4R model. In the resulting hMC4R homology model (A) formation of a stable sodium binding
pocket constituted by hydrophilic amino acid residues Ser1.46 (Ser58, TM1), Asp2 .50 (Asp90, TM2), Ser7.46 (Ser295, TM7), and Asn7 .45 (Asn294, TM7) was observed
(dotted yellow lines indicate potential hydrogen bonds), surrounded by further hydrophilic residues in TM1 (Asn62, Glu61) and in TM2 (Ser94). Sodium binding under
participation of the highly conserved amino acid Asp2 .50 was already reported for the determined structures of protease-activated receptor (PAR) 1 [PDB entry 3VW7
(Zhang et al., 2012)] and PAR2 [PDB entry 5NDD (Cheng et al., 2017)], or as shown in (B) for the high-resolution structure of the A2AR [PDB entry 4EIY (Liu et al.,
2012)]. Potential water molecules additionally surrounding the Na+ ion in a cluster like arrangement. We further note that during our MD simulations (C) the
C-terminus of TM7 moved (∼5.6 Å) toward the membrane (red arrow, MC4R white backbone) in comparison to the template structure of TM7 (blue backbone-ribbon
of S1PR1). This process was accompanied by an inward displacement of H8 (red arrow). This motion resulted in potential polar interactions including salt bridges
between positively charged residues in H8 and a negatively charged side chains in TM7 (Asp298) below to the sodium binding pocket (shown in A). In the template
structure (C, blue backbone) H8 localization and the position of residue 7.49 are similar to the commonly observed features in determined class A GPCR structures.
been used exclusively for metadynamics sampling, in successful
binding using unbiased MD simulation (Limongelli et al., 2013;
Troussicot et al., 2015).
Spontaneous binding of MCL0129 was observed to the ligand-
binding pocket after≈3 µs (Figure 3). The antagonist undergoes
a four-step binding mechanism with three intermediate steps
before settling at the hMC4R in its final position. Both the
N-terminus (Nterm) and ECLs participate in recognition and
spatial orientation of ligand binding. The highly flexible Nterm
acts as a hook that traps the MCL0129 to guide it into the final
binding mode, where the helical part of the Nterm caps the
antagonist as a lid that prevents it leaving the pocket.
In order to verify the final binding mode of MCL0129
obtained from 5 µs unbiased MD simulation, we used
metadynamics simulation of 2 µs collective sampling. We
followed the recently published funnel-metadynamics-
based protocol (Saleh et al., 2017b) to characterize the
global minimum for the hMC4R-MCL0129 complex. The
metadynamics simulation was run independently from the
unbiased MD simulation, using only the final pose of the
MCL0129-hMC4R as starting geometry. We find that the
final binding mode of MCL0129 obtained from unbiased
MD simulation corresponds to the global minimum with
1Gbinding = −11.5 ± 0.3 kcal mol−1 (Figure 3) and Ki ≈
6.5 nM [experimental Ki = 7.99 nM (Pontillo et al., 2005)]. This
binding mode (state 1) is defined by contacts of MCL0129 to
amino acids from the Nterm, ECL1-3 and TM1-7 except for
TM5 (Figures 4A,B and Supplementary Figure S3). Specifically,
hydrogen bonds are formed with Glu29Nterm, Thr1012.61, and
Asp1263.25, in addition to aromatic interactions with Phe511.39,
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FIGURE 3 | (A) Root-mean-square deviation of MCL0129 binding to hMC4R with a scheme for the structure of the non-peptidic antagonist MCL0129.
(B) Free-energy profile for MCL0129 binding to hMC1R, hMC3R, and hMC4R with (C) representatives structures for the observed binding steps at MC4R (states
1–4).
Phe2847.35, and Tyr2686.58 (Figure 4 and Supplementary
Table S1).
Antagonist Versus Agonist Interactions
at hMC4R
The binding mode of MCL0129 matches experimentally
identified interactions of peptidic ligands, including the
endogenous inverse agonist AgRP with MC4R (Yang et al., 2000;
Nickolls et al., 2003; Tao and Segaloff, 2003; Chen et al., 2007;
Tao, 2010). The acidic residues Asp1223.25 and Asp1263.29, which
have been predicted to be directly involved in AgRP binding
(Yang et al., 2000; Nickolls et al., 2003; Tao and Segaloff, 2003;
Chen et al., 2007), form an ionic interaction with the positively-
charged piperazine moiety of MCL0129 in a sandwich-like mode
(one above and one below).
Comparison of the MCL0129 antagonist binding site with
the proposed agonist-binding site (reviewed in Tao, 2010;
Ericson et al., 2017a) provides an explanation for the different
pharmacological effects. The spatial overlap of binding at the
extracellular sides of TM1, TM2, TM3, and TM7 (Figure 4)
suggests that MCL0129 prevents access of the agonist to the
binding pocket, and thus acts by direct competition. MCL0129,
however, does not interact with the specific residues Ile1253.28,
Leu1333.36, Trp2586.48, Phe2616.51, and Met2927.43 (Figure 4)
from the putative agonist-binding pocket (Yang et al., 2000;
Nickolls et al., 2003; Tao and Segaloff, 2003; Chen et al., 2007; Tao,
2010). We assume that these additional contacts located deeper
in the TM bundle define agonist- vs. antagonist-ligand binding
properties.
MCL0129 Selectivity for MCR Subtypes
Amino acid variations of the MCL0129 binding pocket between
all five melanocortin receptors were analyzed to evaluate subtype
selectivity of MCL0129 (Pontillo et al., 2005) (Figure 5). Briefly,
three residues Ser25Nterm, Val461.34, and Tyr2686.58 are found
exclusively in hMC4R, while residues Glu29Nterm and Pro481.36
are shared between hMC4R and MC2R or MC3R, respectively
(Supplementary Figure S1). To test whether these differences
contribute to subtype selectivity, we analyzed MCL0129 binding
to hMC1R and hMC3R by an additional set of MD simulations.
For this purpose, hMC1R and hMC3R subtype models were built
based on the refined hMC4R structure obtained after 5 µs MD
simulations. Next, these subtype models were simulated with the
final docking pose of MCL0129 obtained for hMC4R for 2 µs
of unbiased MD simulation each. The high RMSD values of 7
and 13 Å observed for the MCL0129 ligand with hMC1R and
hMC3R, respectively, reveal high positional variability, indicating
lower affinity to the MCL0129 (Supplementary Figure S2B). The
subsequent metadynamics simulations highlight that MCL0129
indeed binds very weakly (with binding free energies less
than −5 kcal mol−1 for hMC1R and hMC3R, respectively),
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FIGURE 4 | Binding mode of MCL0129. (A) Side view showing MCL0129 in
magenta and potentially contacting residues as blue and cyan sticks.
Residues identified by mutagenesis to interact specifically with agonists are
indicated in green. Those side chains reported to interact with agonist and
overlap with here suggested MCL0129 interactions are indicated cyan.
(B) Top view for the binding mode of MCL0129-hMC4R.
in agreement with the experimental observation that neither
subtype binds MCL0129 up to 10 µM (Pontillo et al., 2005).
DISCUSSION
This study was intended to gain insight into the structure
and specific ligand-binding properties of MC4R, a high-priority
drug target for treating obesity (Zhou and Cai, 2017; Ju et al.,
2018). In the absence of an experimental structure, we used
microsecond-scale MD simulations to study binding of the non-
peptide antagonist MCL0129 to a homology model of human
MC4R (hMC4R). To elucidated subtype selectivity, we evaluated
the binding properties of MCL0129 to structural models of the
homologous hMC1R and hMC3R receptors.
The initial hMC4R model is based on the crystal structure
of the homologous sphingosine 1-phosphate receptor 1 (Hanson
FIGURE 5 | Conservation of ligand binding site residues among the hMCR
group. (A) Red: highly conserved in sequence; Orange: low sequence
conservation (same residue in one further hMCR subtype or maintained
biophysical properties like hydrophobic side chains); Blue: hMC4R specific
amino acids (no sequence conservation); Residues shown as sticks form
potential contacts between hMC4R and MCL0129; Residues shown as lines
are side chains suggested to be involved in action of agonists, but not for
MCL0129 binding. (B) Interaction diagram for the MCL0129-hMC4R complex
color-coded based on the conservation of these interacting residues among
the melanocortin receptors.
et al., 2012), which is characterized by the absence of a proline-
induced kink in TM5 and a disulfide bridge between TM3
and ECL2. The absence of Pro5.50 causes a regular α-helical
conformation different from other GPCRs that have a kink and a
bulge in TM5 (Pro5.50 is approximately 80% conserved) (Sansuk
et al., 2011). The 5 µs unbiased MD simulations of the hMC4R
suggest that this straight TM5 conformation is maintained. The
regular α-helical conformation of TM5 particularly defines the
residues that form the putative ligand-binding site suggested here
(Figure 3). A different set and spatial localization of residues
would become accessible for interaction with the ligand in a
kinked and slightly rotated TM5.
Moreover, we identified a sodium-binding site defined by
amino acid residues in TM 1, 2 and 7, which is known to
impact ligand binding (allosteric effects) and protein stability
(Liu et al., 2012). Key players in this motif are amino acids
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Ser581.46, Asp902.50, Ser2957.46, and Asn2947.45 (Figure 2). This
observation is in general agreement with NMR data on MC4R
and crystal structures of other GPCRs (Zhang et al., 2012; Yun
et al., 2015; Cheng et al., 2017), with the difference that the
putative hMC4R sodium-binding site is located between TM2
and TM7, close to TM1, while in the other GPCRs it is more
located towards TM3.
Finally, we find that in our simulations, a characteristic
outward movement of TM7 by a 5–6 Å in the distal end
relative to the template or other GPCR crystal structures. This
novel structural feature is accompanied by a displacement of
H8 in-between TM1 and TM7 (Figure 2), which indicates high
flexibility of TM7 and H8. In agreement, in the homologous
template structure this part was thermo-stabilized by site-
directed mutations (Supplementary Figure S2).
In accordance with previous computational and experimental
work carried out for other receptors (Dror et al., 2011; Bock et al.,
2012; Kruse et al., 2012; DeVree et al., 2016; Milanos et al., 2016;
Saleh et al., 2016, 2017a,c), our study suggests a stepwise binding
mechanism for the selective non-peptide antagonist MCL0129
to hMC4R. The Nterm plays a key role in ligand binding and
recognition, trapping MCL0129 into its final binding mode.
This binding side of MCL0129 is defined by contacts with
ECL1-3 and TM1-4 and TM6-7, for which we assume a straight
helical conformation in the absence of Pro5.50. MCL0129 is
stabilized by hydrogen bonds with Glu29Nterm, Thr1012.61 and
Asp1263.25, in addition to aromatic interactions with Phe511.39,
Phe2847.35, and Tyr2686.58 (Figures 3, 4 and Supplementary
Table S1).
Partial overlap of the antagonist binding site with the proposed
agonist binding site suggests that MCL0129 directly blocks the
agonist binding (Figure 4A). In addition, several of the contacts
proposed to be essential for agonist binding are missing in the
hMC4R/antagonist complex, thus explaining the antagonistic
properties at hMC4R. We identified several hMC4R residues
as potential selectivity determinants between hMC4R and other
hMCRs (three are hMC4R-specific and two are highly variant),
located in both the 7-TM bundle and the Nterm. Such differences
between MCR subtypes may affect future efforts to design
selective ligands for the MCR’s.
Finally, the ability of MD simulations combined with free-
energy calculations to track and identify intermediate steps of
ligand binding has increasingly contributed to our understanding
of GPCR-ligand interactions and helped to identify potential
binding sites and strategies for SBDD, which remains challenging
for many GPCRs that are still not therapeutically accessible. Our
MC4R-related insights obtained from computational simulations
may pave the way for rational ligand design in the field of
medicinal chemistry targeting the melanocortin systems.
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